Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Non-Current Assets: 2022-2024

Historic Non-Current Assets for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $1.2 million.

  • NewAmsterdam Pharma Co N.V's Non-Current Assets rose 4007.74% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year increase of 4007.74%. This contributed to the annual value of $1.2 million for FY2024, which is 294.44% up from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Non-Current Assets stood at $1.2 million, which was up 294.44% from $306,000 recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's 5-year Non-Current Assets high stood at $1.2 million for FY2024, and its period low was $83,450 during FY2022.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Non-Current Assets value was $306,000 (recorded in 2023), while the average stood at $532,150.
  • Data for NewAmsterdam Pharma Co N.V's Non-Current Assets shows a peak YoY spiked of 294.44% (in 2024) over the last 5 years.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Non-Current Assets (Yearly) stood at $83,450 in 2022, then spiked by 266.69% to $306,000 in 2023, then spiked by 294.44% to $1.2 million in 2024.